Unusually Long Survival (More Than Five Years to More Than 31 Years) in Twelve Patients with Relapsed Medulloblastoma Treated with Antineoplastons in Phase II Studies. CLINICMED. 2015;6(4):1-8. doi:10.24018/clinicmed.2025.6.4.389